NICE: BIVDA HealthTech Update

Mark Chapman Director HealthTech

NICE National Institute for Health and Care Excellence



Note the new name: HealthTech

- HealthTech is now the collective term for Diagnostics, Device & Digital, and for whatever may come next...
- You will hear us increasingly refer to all our evaluations as *HealthTech* evaluations

Why? We have undertaken extensive insights work and many know the element of each of our programmes but few understand the subtle difference, which in part discourages engagement

Why? So we can more appropriate review our offers to *HealthTech* and Medicines.

Why? Internal we are going through a organisational change that will mean all our expertise can be deployed across all the legacy programmes as demand and needs require.

- Please be note the programmes will over adapt to reflect this approach with the NICE wide ambition to have a consistent approach to processes and methods (where appropriate)*
- Please refer to the NICE Business Plan 23/24 and wider strategy available on the NICE website and Board Papers.

Business Plan 2023/24

Draft for discussion

NICE National Institute for Health and Care Excellence



Executive summary

- The world is changing. To play our part in the future, NICE needs to continue to evolve. To better serve people and the health and care system, NICE must transform in 4 ways.
- We are focusing on what matters most, we are creating useful and usable advice, and we are part of a system that continually learns from data and implementation. To do this, we need to build a brilliant organisation.
- Our planning for 2023 and beyond reflects our core purpose, with a particular focus on using health and care resources wisely. Our business plan objectives for 23/24 are:
 - Increase the relevance of our guidance by developing a NICEwide horizon scanning & topic selection function enabled by coordinated stakeholder engagement
 - Increase the real-world impact of our pre-evaluation support by simplifying and improving NICE's early engagement with industry
 - Make our advice easier to access by improving our digital presence
 - Increase the useability of our guidance by incorporating technology appraisals into guidelines, and evolve our supporting resource impact assessment

- Improve NHS decision making in new ways by developing a programme to provide advice on the value of classes of medtech products already in use
- Improve the timeliness of our guidance by implementing improvements to our methods and processes identified last year
- Support implementation of our guidance by improving our measurement approach, and develop an automated uptake and monitoring system for a priority topic
- Build a brilliant organisation by implementing suggestions from crowdsourcing and staff survey including: develop a continuous improvement process and capabilities and adopt NICE-wide talent management approach
- Delivering these objectives will benefit our partners and help deliver our ambition in measurable ways
- In addition, we will continue to deliver our core guidance and make good use of public funds

To better serve people and the health and care system, NICE must transform in 4 ways

NICE is a world-class organisation based on independence, transparency and rigour – that remains our foundation



Build a brilliant organisation

Do we have simple processes and enabling technology and behaviours?

Our business plan objectives for 23/24

Focus on what matters most

Relevance

- Increase the relevance of our guidance by developing a NICE-wide horizon scanning & topic selection function enabled by coordinated stakeholder engagement
- 2. Increase the real-world impact of our pre-evaluation support by simplifying and improving NICE's early engagement with industry

Provide useful and useable advice

Useable

- Make our advice easier to access by improving our digital presence
- Increase the useability of our guidance by incorporating technologies into guidelines, and evolve our supporting resource impact assessment
- Improve the value of NHS purchasing in new ways by developing the programme to provide advice on classes of HealthTech products already in use

Timely

6. Improve the timeliness of our guidance by implementing improvements to our methods and processes identified last year



Constantly learn from data & implementation

3

Learning from real world data

 Support implementation of our guidance by improving our measurement approach, and develop an automated uptake and monitoring system in a priority topic

4

Build a brilliant organisation

 Build a brilliant organisation by implementing suggestions from crowdsourcing and staff survey including: develop a continuous improvement process and capabilities and adopt NICE-wide talent management approach



Increase the real-world impact of our preevaluation support by simplifying and improving NICE's early engagement with industry



Alongside our evaluations of medicines and HealthTech, NICE provides a range of early engagement functions and multiple engagement routes to support innovators from evidence generation through to market access.

We heard from our partners in industry that NICE's range of expert advice offers can be confusing and hard to navigate. We want to ensure we are working with innovators across all areas of NICE's remit, providing expert advice to enable patient access to promising technologies in priority areas.

To improve the experience of industry in their engagement with NICE we will establish a simple early engagement offer and front door to innovators and industry that brings together our current life sciences offers and addresses the needs of our users in industry. This offer will be underpinned by a customer service ethos and a common approach to providing advice to technology developers from the earliest stages of the product development cycle through to patient access and adoption.



Improve NHS decision making in new ways by developing the programme to provide advice on the value of classes of HealthTech products already in use



There is a huge volume and range of HealthTech products on the market and regularly used in the NHS. These products have wide variation in evidence base and price. It is an impossible task for clinicians, managers and commissioners to identify which products offer genuine innovation, and which do and do not offer good value.

NICE's HealthTech programme does not typically evaluate products which are already widely used across the NHS. There is also no standardised method to compare between products of the same class. This means that there is no clear value signal for clinicians, managers, and commissioners, so NHS resources are not always used as effectively as they should be.

To address this situation, we will extend NICE's HealthTech programmes to cover technologies which are already adopted and used in the NHS. NICE's advice for these product classes would help direct purchasing and clinical decisions towards the most clinically and cost effective products, helping improve patient outcomes and make the best use of public money.

NICE

Providing advice on classes of HealthTech products already in use

By the end of 23/24 we will have:

	Q1	Q2	Q3	Q4
Completed evidence review and initial stakeholder engagement to inform evaluative approach			•	
Developed and consulted on new methods and process to consider late- stage multi-tech evaluations	Х. Ч			
Developed an approach to accessing and utilising data for late-stage class-based evaluations				
Launched two pilots of the new approach				•
Developed partnerships for longer-term delivery of data access)

Delivering our objectives will make tangible differences for our users, and lay the foundations for the future




Delivering these objectives will benefit our stakeholders



In addition, we will continue to deliver our core advice and guidance

In 2023/24 we anticipate delivering:



NICE National Institute for Health and Care Excellence